chr11-6609785-C-T

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_004517.4(ILK):​c.918C>T​(p.Ala306Ala) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.246 in 1,613,950 control chromosomes in the GnomAD database, including 50,360 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.22 ( 3906 hom., cov: 33)
Exomes 𝑓: 0.25 ( 46454 hom. )

Consequence

ILK
NM_004517.4 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:5

Conservation

PhyloP100: 0.550

Publications

21 publications found
Variant links:
Genes affected
ILK (HGNC:6040): (integrin linked kinase) This gene encodes a protein with a kinase-like domain and four ankyrin-like repeats. The encoded protein associates at the cell membrane with the cytoplasmic domain of beta integrins, where it regulates integrin-mediated signal transduction. Activity of this protein is important in the epithelial to mesenchymal transition, and over-expression of this gene is implicated in tumor growth and metastasis. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jun 2013]
TAF10 (HGNC:11543): (TATA-box binding protein associated factor 10) Initiation of transcription by RNA polymerase II requires the activities of more than 70 polypeptides. The protein that coordinates these activities is transcription factor IID (TFIID), which binds to the core promoter to position the polymerase properly, serves as the scaffold for assembly of the remainder of the transcription complex, and acts as a channel for regulatory signals. TFIID is composed of the TATA-binding protein (TBP) and a group of evolutionarily conserved proteins known as TBP-associated factors or TAFs. TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors (GTFs) to facilitate complex assembly and transcription initiation. This gene encodes one of the small subunits of TFIID that is associated with a subset of TFIID complexes. Studies with human and mammalian cells have shown that this subunit is required for transcriptional activation by the estrogen receptor, for progression through the cell cycle, and may also be required for certain cellular differentiation programs. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.53).
BP6
Variant 11-6609785-C-T is Benign according to our data. Variant chr11-6609785-C-T is described in ClinVar as Benign. ClinVar VariationId is 137591.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=0.55 with no splicing effect.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.257 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ILKNM_004517.4 linkc.918C>T p.Ala306Ala synonymous_variant Exon 10 of 13 ENST00000299421.9 NP_004508.1 Q13418-1V9HWF0
TAF10NM_006284.4 linkc.*1137G>A 3_prime_UTR_variant Exon 5 of 5 ENST00000299424.9 NP_006275.1 Q12962

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ILKENST00000299421.9 linkc.918C>T p.Ala306Ala synonymous_variant Exon 10 of 13 1 NM_004517.4 ENSP00000299421.4 Q13418-1
TAF10ENST00000299424.9 linkc.*1137G>A 3_prime_UTR_variant Exon 5 of 5 1 NM_006284.4 ENSP00000299424.4 Q12962

Frequencies

GnomAD3 genomes
AF:
0.218
AC:
33089
AN:
151968
Hom.:
3903
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.151
Gnomad AMI
AF:
0.139
Gnomad AMR
AF:
0.214
Gnomad ASJ
AF:
0.250
Gnomad EAS
AF:
0.101
Gnomad SAS
AF:
0.161
Gnomad FIN
AF:
0.294
Gnomad MID
AF:
0.203
Gnomad NFE
AF:
0.260
Gnomad OTH
AF:
0.223
GnomAD2 exomes
AF:
0.228
AC:
57404
AN:
251478
AF XY:
0.226
show subpopulations
Gnomad AFR exome
AF:
0.147
Gnomad AMR exome
AF:
0.237
Gnomad ASJ exome
AF:
0.253
Gnomad EAS exome
AF:
0.107
Gnomad FIN exome
AF:
0.298
Gnomad NFE exome
AF:
0.257
Gnomad OTH exome
AF:
0.238
GnomAD4 exome
AF:
0.249
AC:
363420
AN:
1461864
Hom.:
46454
Cov.:
42
AF XY:
0.247
AC XY:
179468
AN XY:
727228
show subpopulations
African (AFR)
AF:
0.142
AC:
4747
AN:
33480
American (AMR)
AF:
0.236
AC:
10561
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.248
AC:
6491
AN:
26134
East Asian (EAS)
AF:
0.124
AC:
4915
AN:
39700
South Asian (SAS)
AF:
0.163
AC:
14045
AN:
86256
European-Finnish (FIN)
AF:
0.292
AC:
15595
AN:
53416
Middle Eastern (MID)
AF:
0.212
AC:
1220
AN:
5764
European-Non Finnish (NFE)
AF:
0.263
AC:
291935
AN:
1111994
Other (OTH)
AF:
0.230
AC:
13911
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
17632
35264
52897
70529
88161
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
9764
19528
29292
39056
48820
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.218
AC:
33100
AN:
152086
Hom.:
3906
Cov.:
33
AF XY:
0.216
AC XY:
16094
AN XY:
74346
show subpopulations
African (AFR)
AF:
0.151
AC:
6255
AN:
41488
American (AMR)
AF:
0.214
AC:
3268
AN:
15280
Ashkenazi Jewish (ASJ)
AF:
0.250
AC:
869
AN:
3472
East Asian (EAS)
AF:
0.101
AC:
524
AN:
5176
South Asian (SAS)
AF:
0.161
AC:
775
AN:
4820
European-Finnish (FIN)
AF:
0.294
AC:
3107
AN:
10580
Middle Eastern (MID)
AF:
0.204
AC:
60
AN:
294
European-Non Finnish (NFE)
AF:
0.260
AC:
17648
AN:
67952
Other (OTH)
AF:
0.221
AC:
467
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
1321
2641
3962
5282
6603
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
366
732
1098
1464
1830
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.242
Hom.:
3424
Bravo
AF:
0.210
Asia WGS
AF:
0.148
AC:
516
AN:
3478
EpiCase
AF:
0.257
EpiControl
AF:
0.254

ClinVar

Significance: Benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:3
Nov 22, 2013
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Nov 24, 2014
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Ala306Ala in exon 10 of ILK: This variant is not expected to have clinical signi ficance because it does not alter an amino acid residue and is not located withi n the splice consensus sequence. It has been identified in 26.5% (2274/8592) of European American chromosomes from a broad population by the NHLBI Exome Sequenc ing Project (http://evs.gs.washington.edu/EVS; dbSNP rs2292195). -

Feb 07, 2019
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

not provided Benign:1
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Primary familial hypertrophic cardiomyopathy Benign:1
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.53
CADD
Benign
12
DANN
Benign
0.88
PhyloP100
0.55
Mutation Taster
=93/7
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs2292195; hg19: chr11-6631016; COSMIC: COSV54989926; COSMIC: COSV54989926; API